Metallomix
Miami, US · Founded 2021 · Florida corporation
Metallomix is a drug development company working on isotope-selective modulators using non-radioactive stable isotopes (currently zinc-64) to target inflammation and oxidative stress. It develops treatments for oncological, metabolic, neurological, and autoimmune conditions through its ISM (isotope-selective modulation) platform, with ongoing and planned clinical trials.</parameter> <parameter name="founders">[{"full_name": "Max Temnik", "title": "Founder"}]
BiotechLongevityMedical Devices
Founders & leadership
MT
Max TemnikExecutive
SP
Sergei PetukhovNamed on SEC filing
SG
Sergey GurinNamed on SEC filing
Competitors · 6
by search overlapPhenomix Sciences7 shared keywords
Logomix ヒト幹細胞など様々な生物種の細胞機能を効率よく設計・改変する細胞エンジニアリング企業5 shared keywordsGenome engineering-based drug discovery and biomanufacturing R&D support.
BiomX4 shared keywordsBiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security. It targets field-proven products serving homeland security, critical infrastructure, border, transportation, and public safety needs within a Detection, Analysis, and Response operational chain.
Rsc4 shared keywordsThe Royal Society of Chemistry is a professional and scientific organization for the chemical sciences community, offering journal and book publishing, membership, professional recognition, and funding grants. It also supports chemistry education, policy campaigning, and sustainability initiatives.
Tenomix4 shared keywordsTenomix builds an automated robotic platform that combines robotics, ultrasound imaging, and AI to locate lymph nodes in surgically removed cancer tissues during grossing. The system is aimed at pathology teams and healthcare organizations to support cancer staging and diagnostic workflows.
Romix Biosciences3 shared keywordsRomix Bio develops technology to generate deeper insights into disease biology and therapeutic activity. The page provides minimal detail about its specific products or offerings.
Companies competing with Metallomix for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 4 rounds · 2021
▶$1.2MraisedNov 2025 · 1 investors · BiotechnologyRule 506(b)
▶$1.2MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sergei PetukhovExecutive Officer, Director
- Max TemnikExecutive Officer
- Sergey GurinExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.2M
- Minimum investment
- $1M
- First sale
- Oct 2021
- Incorporated
- Corporation, Florida, 2021
- Federal exemptions
- 06b
▶$534.2KraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$534.2KraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Max TemnikExecutive Officer
- Offering amount
- $10M
- Amount sold
- $534.2K
- Minimum investment
- $1M
- First sale
- Oct 2021
- Incorporated
- Corporation, Florida, 2021
- Federal exemptions
- 06b
▶$300KraisedMay 2022 · 1 investors · BiotechnologyRule 506(b)
▶$300KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Max TemnikExecutive Officer
- Offering amount
- $10M
- Amount sold
- $300K
- Minimum investment
- $1M
- First sale
- Oct 2021
- Incorporated
- Corporation, Florida, 2021
- Federal exemptions
- 06b
▶$100KraisedNov 2021 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedNov 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Max TemnikExecutive Officer
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Oct 2021
- Incorporated
- Corporation, Florida, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Metallomix do?
- Metallomix is a drug development company working on isotope-selective modulators using non-radioactive stable isotopes (currently zinc-64) to target inflammation and oxidative stress. It develops treatments for oncological, metabolic, neurological, and autoimmune conditions through its ISM (isotope-selective modulation) platform, with ongoing and planned clinical trials.</parameter> <parameter name="founders">[{"full_name": "Max Temnik", "title": "Founder"}]
- How much funding has Metallomix raised?
- Metallomix has disclosed $2.1M raised across 4 rounds.
- Where is Metallomix headquartered?
- Metallomix is headquartered in Miami, US.